Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research note released on Thursday morning, ThisIsMoney.Co.Uk reports.
Other equities research analysts also recently issued reports about the company. Societe Generale reaffirmed a buy rating on shares of AstraZeneca in a report on Tuesday, September 10th. Barclays reaffirmed an overweight rating on shares of AstraZeneca in a report on Tuesday, October 15th. Kepler Capital Markets lifted their price objective on AstraZeneca from GBX 7,700 ($100.61) to GBX 8,000 ($104.53) and gave the company a buy rating in a report on Tuesday, October 29th. Goldman Sachs Group set a GBX 5,500 ($71.87) price objective on AstraZeneca and gave the company a sell rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on AstraZeneca and gave the company a buy rating in a report on Friday, November 8th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of GBX 7,465.67 ($97.55).
AZN traded down GBX 68 ($0.89) on Thursday, hitting GBX 7,248 ($94.71). 1,418,973 shares of the stock traded hands, compared to its average volume of 2,310,000. AstraZeneca has a 52 week low of GBX 5,312 ($69.41) and a 52 week high of GBX 8,227.88 ($107.51). The company has a current ratio of 0.92, a quick ratio of 0.70 and a debt-to-equity ratio of 148.59. The firm has a market capitalization of $95.09 billion and a PE ratio of 45.47. The business has a fifty day moving average price of GBX 7,164.26 and a two-hundred day moving average price of GBX 6,683.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What causes a stock to be most active?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.